Pharmafile Logo
Pharmafocus logo
Advanced Search

melanoma

Showing 15 posts of 80 posts found.

GSK melanoma drugs beat rival in new study

July 18, 2014
Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma

GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …

News
roche_logo_shadow_7

Roche combination drug for melanoma impresses

July 14, 2014
Research and Development, Sales and Marketing GSK, Roche, Yervoy, braf, mekinist. MEK, melanoma

Roche’s investigational melanoma drug cobimetinib has helped late-stage patients live longer when used in combination with its established skin cancer …

News
BMS image

World’s first anti-PD-1 therapy approved

July 8, 2014
Research and Development, Sales and Marketing BMS, Cancer, melanoma, nivolumab, ono, opdivo

Ono Pharmaceutical has been given the world’s first licence for a new type of cancer treatment on which many researchers’ …

News
gsk image

Mekinist shown EU green light

July 7, 2014
Sales and Marketing CHMP, Cancer, GSK, Tafinlar, braf, mekinist, melanoma

The European Commission has given GlaxoSmithKline’s melanoma drug Mekinist the thumbs-up following a positive opinion in April from the European …

News
Merck image

PD-1 cancer race heats up as Merck takes lead

July 2, 2014
Research and Development, Sales and Marketing ASCO, Cancer, Merck, melanoma, mk3475, oncology, pembrolizumab

Merck’s oncology drug pembrolizumab has taken a big step towards becoming Europe’s first PD-1 cancer treatment as the EMA accepts …

News
BMS image

New BMS cancer treatment shines

June 25, 2014
Research and Development, Sales and Marketing ASCO, BMS, Cancer, Yervoy, braf, melanoma, nivolumab

Bristol-Myers Squibb’s investigational cancer treatment nivolumab has helped patients with the deadliest form of skin cancer to live longer. The …

News
Yervoy image

NICE recommends Yervoy

June 13, 2014
Sales and Marketing BMS, Cancer, Dillon, NHS, NICE, Yervoy, melanoma

Bristol-Myers Squibb has received a lift from the UK’s drugs watchdog, which has recommended its vaccine Yervoy as a first-line …

News

Merck drug shines at ASCO

June 4, 2014
Research and Development, Sales and Marketing ASCO, Cancer, FDA, MK-3475, Merck, melanoma

Merck has shown off one of its investigative cancer drug’s impressive results in advanced head and neck cancer at ASCO …

News
GSK image

GSK cancer vaccine fails again

March 20, 2014
Sales and Marketing Cancer, GSK, MAGE-A3 cancer immunotherapeutic, NSCLC, lung cancer, melanoma

GlaxoSmithKline’s MAGE-A3 cancer immunotherapeutic has delivered another late-stage blow to the firm but it still vows to continue trials.  The …

News
Amgen image

Amgen melanoma vaccine shrinks tumours

March 17, 2014
Research and Development, Sales and Marketing Amgen, Cancer, Yervoy, melanoma, t-vec

Amgen’s investigational cancer vaccine T-vec has managed to shrink the size of advanced melanoma tumours in a late-stage trial. The …

News
Yervoy image

NICE restricts Yervoy use

February 25, 2014
Sales and Marketing BMS, Cancer, NHS, NICE, Yervoy, melanoma

Bristol-Myers Squibb has been dealt a blow by NICE after the UK cost watchdog recommended that the use of skin …

News
Merck image

Merck’s melanoma vaccine impresses

November 19, 2013
Research and Development, Sales and Marketing MK-3475, Merck, Roche, melanoma

Merck has posted impressive results for its new melanoma vaccine MK-3475 as it looks to vie for a place in …

News
gsk_hq_close

GSK’s Tafinlar/Mekinist combo given FDA priority review status

September 17, 2013
Research and Development, Sales and Marketing GSK, Roche, Tafinlar, Zelboraf, melanoma

News
bms

Yervoy setback in prostate cancer

September 16, 2013
Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer

News
GSK image

GSK cancer vaccine fails in Phase III

September 5, 2013
Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III

GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023